This review discusses the evidence in support of the use of budesonide [Budenofalk®] foam enema for the treatment of active rectal and rectosigmoid disease in ulcerative colitis (UC).1 Budesonide is a synthetic steroid with potent local anti-inflammatory effects and is well tolerated due to low systemic bioavailability, with less effect on plasma cortisol levels and potentially minimising side effects reported with traditional corticosteroids.2,3
Budesonide foam enema was registered for the treatment of active rectal and rectosigmoid disease in ulcerative colitis by Australia’s Therapeutic Goods Administration on 12 June 20124 and the product has been listed on the Pharmaceutical Benefits Scheme (PBS) since 28 February 2014.
Independent expert commentary provided by Professor Rupert Leong a Senior Staff Specialist gastroenterologist, Director of Endoscopy and Head of the Inflammatory Bowel Disease Service at Concord Hospital, Clinical Professor of Medicine at University of Sydney and UNSW, and founding director of IBD Sydney, Australia.
Please login below to download this issue (PDF)